SR One
Overview
SR One is a transatlantic biotechnology venture capital firm that partners with entrepreneurs and investment partners to build elite biotechnology companies. The firm focuses on translating innovative technologies and scientific discoveries into next-generation medicines with the potential to benefit patients with significant unmet medical needs. SR One takes a back-and-build approach to its investments, focusing on companies with strong underlying fundamentals, a clearly defined development pathway, and novel approaches to addressing diseases.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Crystalys Therapeutics | Jul 2026 | Series B | Co-investor |
| Fore Biotherapeutics | Jul 2026 | Series D-2 Extension | Lead |
| Avenzo Therapeutics | Jun 2026 | Private Placement | Co-investor |
| Windward Bio | May 2026 | VC Round | Co-investor |
| ImmuneBiotech | May 2026 | Growth Equity | Co-investor |
Key People
Simeon George
Chief Executive Officer and Co-Founder
Rajeev Dadoo
Managing Partner
Christopher Chai
Venture Partner
Jake Bauer
Venture Partner
Matthew Patterson
Venture Partner
peter van vlasselaer
Venture Partner
Jake Nunn
Partner
Jill Carroll
Partner
Michael Diem
Partner
Katarina Pance
Principal
Laetitia Schwab
Principal
Mahesh Kudari
Biotech Venture Capital
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
